UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000016032
Receipt number R000018604
Scientific Title Feasibility Study of Accelerated Partial Breast Irradiation using SAVI (Strut Adjusted Volume Implant)
Date of disclosure of the study information 2014/12/22
Last modified on 2020/01/06 13:57:40

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Feasibility Study of Accelerated Partial Breast Irradiation using SAVI (Strut Adjusted Volume Implant)

Acronym

Feasibility Study of Accelerated Partial Breast Irradiation using SAVI (Strut Adjusted Volume Implant)

Scientific Title

Feasibility Study of Accelerated Partial Breast Irradiation using SAVI (Strut Adjusted Volume Implant)

Scientific Title:Acronym

Feasibility Study of Accelerated Partial Breast Irradiation using SAVI (Strut Adjusted Volume Implant)

Region

Japan


Condition

Condition

breast cancer

Classification by specialty

Radiology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the feasibility, safety and cosmesis of accelerated partial breast irradiation using SAVI for early breast cancer patients.

Basic objectives2

Safety

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

the rate for completion of protocol treatment

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Device,equipment

Interventions/Control_1

accelerated partial breast irradiation using SAVI

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

45 years-old <=

Age-upper limit


Not applicable

Gender

Female

Key inclusion criteria

1. Clinically tumor diameter is less than or equal to 3 cm, and planed to be treated with lumpectomy.
2. Clinically negative nodes and negative metastases.
3. Negative multicentric disease(excluding tumors in different quadrants of the breast, or tumors separated by at least 4 cm)
4. Histologically ductal carcinoma
5. Negative,inked histologic margins of lumpectomy or reexcision specimen to be confirmed prior to introducing the radiation sources. Margins are positive if there is invasive or noninvasive tumor at the inked resection margin.
6. Negative axillary nodes and/or a negative sentinel node. No axillary dissection is needed if pure DCIS.
7. Hormonal manipulation therapy is allowed. Chemotherapy planned for 2 weeks after removal of brachytherapy catheters is permitted.
8. Female
9. Age 45 years or older
10. Written Informed Consent obtained

Key exclusion criteria

1. Patients with operation other than lumpectomy.
2. Patients with pure lobular
3. Patient with nonepithelial breast malignancies such as sarcoma or lymphoma.
4. Patients with proven multicentric disease (tumors in different quadrants of the breast, or tumors separated by at least 4 cm) with other clinically or radiographically suspicious lesions in the ipsilateral breast unless confirmed to be negative for malignancy by biopsy.
5. Patients with lumpectomies so extensive that the cosmetic result is fair or poor prior to brachytherapy.
6. Patients whose lumpectomy cavity is not easily delineated by standard breast imaging or contrast injected into the biopsy cavity.
7. Time between final definitive breast procedure to beginning brachytherapy is greater than 8 weeks.
8. Prior non-hormonal therapy for the present breast cancer, including radiation therapy or chemotherapy.
9. Prior Ipsilateral breast or thoracic RT for any condition.
10. Patients who are pregnant or lactating.
11. Patients with collagen vascular diseases, specifically systemic lupus erythematosis, scleroderma, or dermatomyositis with a CPK level above normal or with an active skin rash.
12. Patients with psychiatric or addictive disorders or other conditions which would preclude obtaining informed consent or completing the full series of brachytherapy treatments on an outpatient basis.
13. Other malignancy, except non-melanoma skin cancer or cervical cancer in-situ, < 5 years prior to participation in this study; the disease free interval from any prior carcinoma must be continuous.
14. Patients with a diagnosis of insulin-dependent diabetes.

Target sample size

30


Research contact person

Name of lead principal investigator

1st name Jun
Middle name
Last name Itami

Organization

National Cancer Center Hospital

Division name

Department of Radiation Oncology

Zip code

1040045

Address

5-1-1 Tsukiji, Chuo-ku, Tokyo

TEL

03-3542-2511

Email

jitami@ncc.go.jp


Public contact

Name of contact person

1st name Kana
Middle name
Last name Takahashi

Organization

National Cancer Center Hospital

Division name

Department of Radiation Oncology

Zip code

1040045

Address

5-1-1 Tsukiji, Chuo-ku, Tokyo

TEL

03-3542-2511

Homepage URL


Email

kantakah@ncc.go.jp


Sponsor or person

Institute

National Cancer Center Hospital

Institute

Department

Personal name



Funding Source

Organization

none

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

National Cancer Center Hospital

Address

5-1-1 Tsukiji, Chuo-ku, Tokyo

Tel

03-3542-2511

Email

NCC_IRBoffice@ml.res.ncc.go.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2014 Year 12 Month 22 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

7

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2014 Year 07 Month 01 Day

Date of IRB

2014 Year 06 Month 26 Day

Anticipated trial start date

2014 Year 08 Month 15 Day

Last follow-up date

2021 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2014 Year 12 Month 22 Day

Last modified on

2020 Year 01 Month 06 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000018604


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name